![Kara Stancell](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Kara J.
Stancell is currently the VP-Investor Relations & Corporate Communications at Clarus Therapeutics Holdings, Inc. She previously worked as the Executive Director-Investor Relations at Medicis Pharmaceutical Corp.
from 2010 to 2011 and as the VP-Investor Relations & Corporate Communications at Dermavant Sciences, Inc. from 2018 to 2021.
Postes actifs de Kara Stancell
| Sociétés | Poste | Début |
|---|---|---|
| CLARUS THERAPEUTICS HOLDINGS, INC. | Investor Relations Contact | - |
Anciens postes connus de Kara Stancell
| Sociétés | Poste | Fin |
|---|---|---|
Dermavant Sciences, Inc.
 Dermavant Sciences, Inc. BiotechnologyHealth Technology Operates as a a biotechnology company focused on dermatology | Investor Relations Contact | 01/03/2021 |
| MEDICIS PHARMACEUTICAL CORP | Public Communications Contact | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Medicis Pharmaceutical Corp.
 Medicis Pharmaceutical Corp. Pharmaceuticals: MajorHealth Technology Develops and markets pharmaceutical products for dermatological usages | Health Technology |
Dermavant Sciences, Inc.
Dermavant Sciences, Inc. BiotechnologyHealth Technology Operates as a a biotechnology company focused on dermatology | Health Technology |
Clarus Therapeutics Holdings, Inc.
 Clarus Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops oral T-replacement therapies | Health Technology |
